Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Vanja Zeremski, Enver Aydilek, Akhil Behringer, Franziska Brunner, Tobias Ronny Haage, Mathias Haenel, Igor Age Kos, William Hermann Krueger, Georg Lenz, Vadim Lesan, Jessica Schneider, Christian R Schultze-Florey, Evgenii Shumilov, Thomas Weber, Gerald Georg Wulf, Vladan Vucinic, Dimitrios Mougiakakos Blood Advances 2025 December 18

https://read.qxmd.com/read/41411524/early-car-t-cell-therapy-in-relapsed-refractory-large-b-cell-lymphoma-is-associated-with-lower-hematotoxicity-burden?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Dec 18, 2025: Blood Advances

HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer. Seohyuk Lee, Adriana M Kahn, Mariya Rozenblit, Mridula A George, Cristina Naranjo Ortiz, Maryam B Lustberg Cancer Medicine 2025 December

https://read.qxmd.com/read/41361931/her2-targeted-antibody-drug-conjugate-toxicities-in-breast-cancer?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer. HER2-targeted antibody-drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2-targeted ADCs, trastuzumab deruxtecan and trastuzumab .. Dec 2025: Cancer Medicine

An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder. Wei-Zhen Bai, Shi-Yu Zhou, Yuan-Yuan Mou, Liao Peng, Ling-Li Li Medicine (Baltimore) 2025 December 5

https://read.qxmd.com/read/41366890/an-updated-meta-analysis-of-head-to-head-trials-comparing-the-efficacy-safety-and-adherence-of-mirabegron-and-vibegron-in-overactive-bladder?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder. This updated meta-analysis aimed to compare the efficacy, safety, and treatment adherence of mirabegron and vibegron in patients with overactive bladder with he.. Dec 5, 2025: Medicine (Baltimore)

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial. Everett Meyer, Amandeep Salhotra, Arpita Gandhi, Jeremy Pantin, Sagar S Patel, Rasmus T Hoeg, Alexandra Gomez-Arteaga, Rawan G Faramand, Roni Tamari, Edmund K Waller, Satyajit Kosuri, Antonio M Jimenez Jimenez, Jennifer Holter-Chakrabarty, Bhagirathbhai Dholaria, Yi-Bin Chen, Betty K Hamilton, John M Magenau, Alireza Eghtedar, Joshua M Murray, Anna Pavlova, Nathaniel B Fernhoff, James Scott McClellan, Scott Killian, Ai Li, Robert S Negrin, Caspian Oliai

https://read.qxmd.com/read/41385341/orca-t-versus-allogeneic-hematopoietic-stem-cell-transplantation-precision-t-a-multicenter-randomized-phase-3-trial?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial. To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin in.. Dec 12, 2025: Blood

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50. A De Giglio, L Zullo, A Di Federico, M Cani, M Aldea, D Soldato, F G Dall'Olio, F Mantuano, F Sperandi, V Favorito, A Sadowska, L E L Hendriks, T Gorria, L Mezquita, F Tabbò, S Novello, F Gelsomino, B Besse, A Ardizzoni

https://read.qxmd.com/read/41252810/immunotherapy-beyond-progression-combined-with-platinum-based-chemotherapy-after-primary-resistance-to-first-line-immunotherapy-in-patients-with-advanced-nsclc-and-pd-l1-50?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50. Primary resistance to immune checkpoint inhibitors (ICIs) remains a major challenge in patients with advanced non-small-cell lung cancer (NSCLC) and programmed .. Nov 17, 2025: ESMO Open

Ultrasound indicators of organ venous congestion: a narrative review. Zouheir Ibrahim Bitar, Ossama Sajeh Maadarani, Mohamad Bitar

https://read.qxmd.com/read/41251929/ultrasound-indicators-of-organ-venous-congestion-a-narrative-review?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Ultrasound indicators of organ venous congestion: a narrative review. Acute kidney injury and other organ dysfunction in the setting of heart failure are primarily determined by a low cardiac output status and venous congestion, w.. Nov 18, 2025: Annals of Intensive Care

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Alberto Martínez-Castelao, José Luis Górriz, Beatriz Fernández-Fernández, María José Soler, Juan F Navarro-González

https://read.qxmd.com/read/41375628/diabetes-mellitus-and-chronic-kidney-disease-the-future-is-being-surpassed?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health is.. Nov 23, 2025: Journal of Clinical Medicine